Climb Bio, Inc.
CLYM
$2.33
-$0.15-6.05%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.86% | 197.34% | 156.45% | 156.23% | 59.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 126.54% | 665.99% | 257.15% | 75.64% | -21.20% |
| Operating Income | -126.54% | -665.99% | -257.15% | -75.64% | 21.20% |
| Income Before Tax | 84.21% | -1,124.57% | -131.15% | -124.17% | -951.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 84.21% | -1,124.57% | -131.15% | -124.17% | -951.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 84.21% | -1,124.57% | -131.15% | -124.17% | -951.51% |
| EBIT | -126.54% | -665.99% | -257.15% | -75.64% | 21.20% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 92.91% | -401.63% | 1.66% | 9.48% | -829.87% |
| Normalized Basic EPS | -20.45% | -399.25% | 0.00% | 40.12% | 36.36% |
| EPS Diluted | 92.91% | -401.63% | 1.66% | 9.48% | -829.87% |
| Normalized Diluted EPS | -20.45% | -399.25% | 0.00% | 40.12% | 36.36% |
| Average Basic Shares Outstanding | 122.69% | 144.09% | 135.09% | 147.55% | 13.07% |
| Average Diluted Shares Outstanding | 122.69% | 144.09% | 135.09% | 147.55% | 13.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |